MCID: HRT032
MIFTS: 76

Heart Disease

Categories: Cardiovascular diseases, Genetic diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 15 17 3
Congenital Heart Disease 12 30 56 6 15 17 74
Congenital Heart Defects 12 30 6 44 15 3 64
Heart Diseases 45 74
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 41
Congenital Heart Disorder 77
Heart Defects, Congenital 45
Heart Disease, Congenital 41
Congestive Heart Failure 74
Heart Defects Congenital 56
Congenital Heart Defect 12
Heart-Congenital Defect 12
Heart Malformation 12
Heart Failure 74
Heart Defect 12

Classifications:



Summaries for Heart Disease

MedlinePlus : 44 A congenital heart defect is a problem with the structure of the heart. It is present at birth. Congenital heart defects are the most common type of birth defect. The defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. They can disrupt the normal flow of blood through the heart. The blood flow can slow down, go in the wrong direction or to the wrong place, or be blocked completely. Doctors use a physical exam and special heart tests to diagnose congenital heart defects. They often find severe defects during pregnancy or soon after birth. Signs and symptoms of severe defects in newborns include Rapid breathing Cyanosis - a bluish tint to the skin, lips, and fingernails Fatigue Poor blood circulation Many congenital heart defects cause few or no signs and symptoms. They are often not diagnosed until children are older. Many children with congenital heart defects don't need treatment, but others do. Treatment can include medicines, catheter procedures, surgery, and heart transplants. The treatment depends on the type of the defect, how severe it is, and a child's age, size, and general health. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart disease, is related to heart, malformation of and congestive heart failure, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Heart Disease is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are Cardiac conduction and Human Embryonic Stem Cell Pluripotency. The drugs Ranolazine and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and muscle

Disease Ontology : 12 A cardiovascular system disease that involves the heart.

CDC : 3 Here’s how to reduce sodium intake at home and on the go.

PubMed Health : 64 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 77 A congenital heart defect (CHD), also known as a congenital heart anomaly or congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1466)
# Related Disease Score Top Affiliating Genes
1 heart, malformation of 34.2 MYH6 TBX5
2 congestive heart failure 33.4 HOTAIR MYH6 NPPA NPPB
3 cardiac arrest 32.8 NPPB RYR2 SCN5A
4 patent ductus arteriosus 1 32.6 GATA4 NKX2-5 NPPB
5 hypoplastic left heart syndrome 32.6 MYH6 NKX2-5 NPPA NPPB
6 syncope 32.5 NPPA NPPB SCN5A
7 double outlet right ventricle 32.5 GATA4 NKX2-5 ZIC3
8 familial progressive cardiac conduction defect 32.5 NKX2-5 SCN5A
9 atrial standstill 1 32.1 MIR320A MYH6 NPPB SCN5A
10 dilated cardiomyopathy 32.0 GATA4 MIR196A2 MYH6 NKX2-5 NPPA NPPB
11 atrioventricular block 32.0 GATA4 NKX2-5 NPPB SCN5A TBX5
12 atrial fibrillation 31.8 NPPA NPPB RYR2 SCN5A TBX5
13 aortic valve disease 2 31.8 NPPA NPPB TBX5
14 tricuspid valve disease 31.7 NKX2-5 NPPB ZIC3
15 left ventricular noncompaction 31.6 MYH6 NKX2-5 RYR2 SCN5A
16 atrial standstill 31.4 NPPA SCN5A
17 atrial heart septal defect 31.4 GATA4 MYH6 NKX2-5 TBX5
18 tetralogy of fallot 31.3 GATA4 MKKS NKX2-5 NPPA NPPB TBX5
19 patent foramen ovale 31.3 GATA4 MYH6 NKX2-5 TBX5
20 ventricular fibrillation, paroxysmal familial, 1 31.3 NKX2-5 RYR2 SCN5A
21 aortic valve disease 1 31.2 H19 NKX2-5 NPPB
22 mitral valve insufficiency 31.1 NPPA NPPB TBX5
23 ventricular septal defect 31.0 GATA4 NKX2-5 NPPB TBX5 ZIC3
24 transposition of the great arteries 30.9 NKX2-5 ZIC3
25 pulmonary valve stenosis 30.7 GATA4 SCN5A
26 familial sick sinus syndrome 30.7 MYH6 SCN5A
27 pulmonary valve disease 30.6 GATA4 TBX5
28 third-degree atrioventricular block 30.6 NPPB SCN5A
29 ebstein anomaly 30.5 GATA4 NKX2-5 NPPB
30 holt-oram syndrome 30.5 MYH6 NKX2-5 TBX5
31 atrioventricular septal defect 30.5 GATA4 NKX2-5 TBX5
32 central sleep apnea 30.4 NPPA NPPB
33 heart septal defect 30.3 GATA4 NKX2-5 TBX5
34 leukemia, acute myeloid 29.1 ABL1 HOTAIR MIR210 MIR320A
35 coronary heart disease 1 12.6
36 deafness, congenital heart defects, and posterior embryotoxon 12.6
37 short stature, developmental delay, and congenital heart defects 12.6
38 multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects 12.5
39 hypertensive heart disease 12.5
40 congenital heart defects, multiple types, 3 12.4
41 congenital heart defects, multiple types, 4 12.4
42 congenital heart defects, multiple types, 5 12.4
43 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 12.4
44 congenital heart defects and ectodermal dysplasia 12.4
45 rheumatic heart disease 12.4
46 congenital heart defects, multiple types, 6 12.4
47 ischemic heart disease 12.4
48 congenital heart defects, hamartomas of tongue, and polysyndactyly 12.4
49 structural heart defects and renal anomalies syndrome 12.3
50 coronary heart disease 5 12.3

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 316)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

MGI Mouse Phenotypes related to Heart Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ABL1 GATA4 MKKS MYH6 NKX2-5 NPPA
2 muscle MP:0005369 9.23 ABL1 GATA4 MYH6 NKX2-5 NPPA RYR2

Drugs & Therapeutics for Heart Disease

PubMedHealth treatment related to Heart Disease: 64

Although many children who have congenital heart defects don't need treatment, some do. Doctors repair congenital heart defects with catheter procedures or surgery.Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects.The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health.Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
2
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
3
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 73963-72-1 2754
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177 70789204
8
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
9
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
10
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134523-00-5 60823
11
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72956-09-3 2585
12
Clonidine Approved Phase 4,Not Applicable 4205-90-7 2803
13
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
14
Etomidate Approved Phase 4,Phase 2 33125-97-2 36339 667484
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
16
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
17
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 28523-86-6 5206
18
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 71273 175805
19
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
20
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
21
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
22
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
23
Nicorandil Approved, Investigational Phase 4,Not Applicable 65141-46-0 47528
24
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
25
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
26
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
27
Adalimumab Approved Phase 4,Not Applicable 331731-18-1 16219006
28
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
29
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137862-53-4 60846
30
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 98-92-0 936
31
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
32
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
33
Verapamil Approved Phase 4,Phase 2,Phase 3,Not Applicable 52-53-9 2520
34
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
35
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3930-20-9, 959-24-0 5253
36
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-04-2
37
Chromium Approved Phase 4,Phase 3,Not Applicable 7440-47-3 27668
38
Cobalt Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7440-48-4 104729
39
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
40
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
41
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
42
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 57-83-0 5994
43
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
44
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
45
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
46
Exenatide Approved, Investigational Phase 4,Phase 3,Not Applicable 141758-74-9 15991534
47
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
48
Ethinyl Estradiol Approved Phase 4,Phase 1,Not Applicable 57-63-6 5991
49
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
50
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 163222-33-1 150311

Interventional clinical trials:

(show top 50) (show all 10078)
# Name Status NCT ID Phase Drugs
1 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
2 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
4 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
5 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
6 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
7 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
8 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
9 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
10 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
11 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
12 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
13 Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery Unknown status NCT01457586 Phase 4
14 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
15 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
16 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
17 Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
18 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) Unknown status NCT02044250 Phase 4 Clopidogrel;Aspirin
19 Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
20 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
21 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
22 Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography Unknown status NCT01260558 Phase 4
23 Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography Unknown status NCT01230723 Phase 4
24 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
25 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
26 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
27 Enteral Nutrition After Cardiovascular Surgery Unknown status NCT01432769 Phase 4
28 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
29 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
30 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
31 The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study Unknown status NCT01623193 Phase 4
32 Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction Unknown status NCT00888758 Phase 4
33 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
34 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
35 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
36 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
37 Patent Versus Generic Clopidogrel in Acute Coronary Syndrome Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
38 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
39 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
40 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
41 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
42 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
43 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
44 Therapy With Verapamil or Carvedilol in Chronic Heart Failure Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
45 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
46 Does Sildenafil Protect Against Pulmonary Related Complications Following Cardiopulmonary Bypass? Unknown status NCT00350441 Phase 4 Sildenafil Citrate
47 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
48 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
49 Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay Unknown status NCT01023360 Phase 4 Clopidogrel and proton pump inhibitors
50 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 30
2 Congenital Heart Defects 30

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

42
Heart, Testes, Endothelial, Kidney, Lung, Brain, Bone

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 16248)
# Title Authors Year
1
Psychological traits, heart rate variability, and risk of coronary heart disease in healthy aging women - the Women's Health Initiative. ( 30688770 )
2019
2
Popeye's sign, heart disease, and amyloidosis. ( 30799016 )
2019
3
Multi-state models of transitions in depression and anxiety symptom severity and cardiovascular events in patients with coronary heart disease. ( 30845176 )
2019
4
LIM kinase 1 acts as a profibrotic mediator in permanent atrial fibrillation patients with valvular heart disease. ( 30837367 )
2019
5
Diagnostic Usefulness of Chest Radiography During Preoperative Assessment of Patients With Atrial Fibrillation and Structural Heart Disease. ( 30765205 )
2019
6
Atrial fibrillation in adults with congenital heart disease. ( 30712848 )
2019
7
Circular RNA expression profiles of persistent atrial fibrillation in patients with rheumatic heart disease. ( 30587718 )
2019
8
Impact  of an integral assistance model between primary care and cardiology on the management of patients with ischemic heart disease or atrial fibrillation. ( 30547674 )
2019
9
Involvement of Apelin/APJ Axis in Thrombogenesis in Valve Heart Disease Patients with Atrial Fibrillation. ( 30518720 )
2019
10
Associations of calcium and dairy product intakes with all-cause, all-cancer, colorectal cancer, and coronary heart disease mortality among older women in the Iowa Women's Health Study. ( 30834851 )
2019
11
Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. ( 30655975 )
2019
12
Out-of-hospital cardiac arrest in adults with congenital heart disease: More questions than answers? ( 30609960 )
2019
13
Resuscitation for out-of-hospital cardiac arrest in adults with congenital heart disease. ( 30414749 )
2019
14
Targeted next‑generation sequencing for research and diagnostics in congenital heart disease, and cleft lip and/or palate. ( 30896870 )
2019
15
Coronary stenosis and left ventricular function - Major prognostic factors in patients with ischemic heart disease: Has something changed in the era of "precision medicine"? ( 30545618 )
2019
16
Pulse oximetry screening for critical congenital heart disease: a comparative study of cohorts over 11 years ( 30332903 )
2019
17
Impact of Family Socioeconomic Status on Health-Related Quality of Life in Children With Critical Congenital Heart Disease. ( 30563422 )
2019
18
Brain microstructural development in neonates with critical congenital heart disease: An atlas-based diffusion tensor imaging study. ( 30677732 )
2019
19
Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018. ( 30730872 )
2019
20
Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. ( 30886334 )
2019
21
Clarifying the Concept of Depression in Women With Coronary Heart Disease. ( 30864985 )
2019
22
Effect of text messaging on depression in patients with coronary heart disease: a substudy analysis from the TEXT ME randomised controlled trial. ( 30787075 )
2019
23
Psychological distress in adults with congenital heart disease: focus beyond depression. ( 30698116 )
2019
24
Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation developed under the auspices of the ESC Committee for Practice Guidelines. ( 30698764 )
2019
25
Higher rates of depression among women living with Coronary Heart Disease are associated with poorer treatment outcomes and prognosis. ( 30661009 )
2019
26
Right-Sided Subcutaneous Implantable Cardioverter Defibrillator System Implantation in a Patient with Complex Congenital Heart Disease and Dextrocardia: A Case Report and Literature Review. ( 30867968 )
2019
27
Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. ( 30651799 )
2019
28
Maternal LINE-1 DNA Methylation and Congenital Heart Defects in Down Syndrome. ( 30787943 )
2019
29
Surgical Treatment for Congenital Heart Defects in Down Syndrome Patients. ( 30810666 )
2019
30
Prosthetic pulmonary valve and conduit endocarditis in congenital heart disease. ( 30791694 )
2019
31
Epilepsy and seizures in children with congenital heart disease: A prospective study. ( 30557820 )
2019
32
Long-term outcomes of cardiac resynchronization therapy in adult congenital heart disease. ( 30908673 )
2019
33
Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study. ( 30909590 )
2019
34
Lower clearance of sodium tanshinone IIA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis. ( 30910058 )
2019
35
Genetic polymorphisms in MTR are associated with non-syndromic congenital heart disease from a family-based case-control study in the Chinese population. ( 30911047 )
2019
36
A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease. ( 30911318 )
2019
37
Oligosymptomatic cyanotic heart disease in an adult with a univentricular heart. ( 30912113 )
2019
38
Heart Rate Response During Treadmill Exercise Test in Children and Adolescents With Congenital Heart Disease. ( 30915321 )
2019
39
Explaining the decline in coronary heart disease mortality rates in Japan: Contributions of changes in risk factors and evidence-based treatments between 1980 and 2012. ( 30826193 )
2019
40
Living With, and Caring for, Congenital Heart Disease in Australia: Insights From the Congenital Heart Alliance of Australia and New Zealand Online Survey. ( 30826267 )
2019
41
Population-based study of congenital heart disease and revisits after pediatric tonsillectomy. ( 30828616 )
2019
42
Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years. ( 30828782 )
2019
43
Reducing Coronary Heart Disease Risk Through Treatment of Insomnia Using Web-Based Cognitive Behavioral Therapy for Insomnia: A Methodological Approach. ( 30829067 )
2019
44
Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy. ( 30832963 )
2019
45
Carcinoid Heart Disease: Review of Current Knowledge. ( 30833833 )
2019
46
Statins for the Primary Prevention of Coronary Heart Disease. ( 30834266 )
2019
47
Association of NKX2-5, GATA4, and TBX5 polymorphisms with congenital heart disease in Egyptian children. ( 30834692 )
2019
48
Patient empowerment and its correlates in young persons with congenital heart disease. ( 30834772 )
2019
49
Relationship of Neighborhood Greenness to Heart Disease in 249 405 US Medicare Beneficiaries. ( 30835593 )
2019
50
Predictors of extracorporeal membrane oxygenation support after surgery for adult congenital heart disease in children's hospitals. ( 30835967 )
2019

Variations for Heart Disease

ClinVar genetic disease variations for Heart Disease:

6 (show top 50) (show all 76)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTCH1 NM_000264.4(PTCH1): c.2945G> A (p.Arg982Gln) single nucleotide variant Uncertain significance rs145924695 GRCh37 Chromosome 9, 98220518: 98220518
2 PTCH1 NM_000264.4(PTCH1): c.2945G> A (p.Arg982Gln) single nucleotide variant Uncertain significance rs145924695 GRCh38 Chromosome 9, 95458236: 95458236
3 MYH6 NM_002471.3(MYH6): c.2575G> T (p.Gly859Trp) single nucleotide variant Uncertain significance rs369274077 GRCh37 Chromosome 14, 23863387: 23863387
4 MYH6 NM_002471.3(MYH6): c.2575G> T (p.Gly859Trp) single nucleotide variant Uncertain significance rs369274077 GRCh38 Chromosome 14, 23394178: 23394178
5 NKX2-5 NM_004387.3(NKX2-5): c.443C> A (p.Ala148Glu) single nucleotide variant Pathogenic rs864321649 GRCh38 Chromosome 5, 173233101: 173233101
6 NKX2-5 NM_004387.3(NKX2-5): c.443C> A (p.Ala148Glu) single nucleotide variant Pathogenic rs864321649 GRCh37 Chromosome 5, 172660104: 172660104
7 NKX2-5 NM_004387.3(NKX2-5): c.391G> A (p.Glu131Lys) single nucleotide variant Pathogenic rs864321648 GRCh38 Chromosome 5, 173233153: 173233153
8 NKX2-5 NM_004387.3(NKX2-5): c.391G> A (p.Glu131Lys) single nucleotide variant Pathogenic rs864321648 GRCh37 Chromosome 5, 172660156: 172660156
9 NKX2-5 NM_004387.3(NKX2-5): c.335-1G> T single nucleotide variant Pathogenic rs864321645 GRCh38 Chromosome 5, 173233210: 173233210
10 NKX2-5 NM_004387.3(NKX2-5): c.335-1G> T single nucleotide variant Pathogenic rs864321645 GRCh37 Chromosome 5, 172660213: 172660213
11 NKX2-5 NM_004387.3(NKX2-5): c.335-12G> A single nucleotide variant Uncertain significance rs864321646 GRCh38 Chromosome 5, 173233221: 173233221
12 NKX2-5 NM_004387.3(NKX2-5): c.335-12G> A single nucleotide variant Uncertain significance rs864321646 GRCh37 Chromosome 5, 172660224: 172660224
13 NKX2-5 NM_004387.3(NKX2-5): c.335-20G> A single nucleotide variant Uncertain significance rs864321647 GRCh38 Chromosome 5, 173233229: 173233229
14 NKX2-5 NM_004387.3(NKX2-5): c.335-20G> A single nucleotide variant Uncertain significance rs864321647 GRCh37 Chromosome 5, 172660232: 172660232
15 NKX2-5 NM_004387.3(NKX2-5): c.182C> G (p.Ala61Gly) single nucleotide variant Pathogenic rs864321650 GRCh38 Chromosome 5, 173234902: 173234902
16 NKX2-5 NM_004387.3(NKX2-5): c.182C> G (p.Ala61Gly) single nucleotide variant Pathogenic rs864321650 GRCh37 Chromosome 5, 172661905: 172661905
17 GATA4 NM_002052.4(GATA4): c.682T> A (p.Trp228Arg) single nucleotide variant Pathogenic rs864321702 GRCh37 Chromosome 8, 11606493: 11606493
18 GATA4 NM_002052.4(GATA4): c.23C> A (p.Ala8Asp) single nucleotide variant Pathogenic rs864321698 GRCh37 Chromosome 8, 11565844: 11565844
19 GATA4 NM_002052.4(GATA4): c.23C> A (p.Ala8Asp) single nucleotide variant Pathogenic rs864321698 GRCh38 Chromosome 8, 11708335: 11708335
20 GATA4 NM_002052.4(GATA4): c.25G> A (p.Ala9Thr) single nucleotide variant Pathogenic rs864321699 GRCh37 Chromosome 8, 11565846: 11565846
21 GATA4 NM_002052.4(GATA4): c.25G> A (p.Ala9Thr) single nucleotide variant Pathogenic rs864321699 GRCh38 Chromosome 8, 11708337: 11708337
22 GATA4 NM_002052.4(GATA4): c.27C> A (p.Ala9=) single nucleotide variant Pathogenic rs864321703 GRCh37 Chromosome 8, 11565848: 11565848
23 GATA4 NM_002052.4(GATA4): c.27C> A (p.Ala9=) single nucleotide variant Pathogenic rs864321703 GRCh38 Chromosome 8, 11708339: 11708339
24 GATA4 NM_002052.4(GATA4): c.383A> T (p.Glu128Val) single nucleotide variant Pathogenic rs864321700 GRCh37 Chromosome 8, 11566204: 11566204
25 GATA4 NM_002052.4(GATA4): c.383A> T (p.Glu128Val) single nucleotide variant Pathogenic rs864321700 GRCh38 Chromosome 8, 11708695: 11708695
26 GATA4 NM_002052.4(GATA4): c.397A> T (p.Ser133Cys) single nucleotide variant Pathogenic rs864321701 GRCh38 Chromosome 8, 11708709: 11708709
27 GATA4 NM_002052.4(GATA4): c.397A> T (p.Ser133Cys) single nucleotide variant Pathogenic rs864321701 GRCh37 Chromosome 8, 11566218: 11566218
28 GATA4 NM_002052.4(GATA4): c.682T> A (p.Trp228Arg) single nucleotide variant Pathogenic rs864321702 GRCh38 Chromosome 8, 11748984: 11748984
29 GATA4 NM_002052.4(GATA4): c.997+2T> G single nucleotide variant Pathogenic rs864321705 GRCh37 Chromosome 8, 11612644: 11612644
30 GATA4 NM_002052.4(GATA4): c.997+2T> G single nucleotide variant Pathogenic rs864321705 GRCh38 Chromosome 8, 11755135: 11755135
31 GATA4 NM_002052.4(GATA4): c.1263C> T (p.Ser421=) single nucleotide variant Pathogenic rs864321704 GRCh38 Chromosome 8, 11758409: 11758409
32 GATA4 NM_002052.4(GATA4): c.1263C> T (p.Ser421=) single nucleotide variant Pathogenic rs864321704 GRCh37 Chromosome 8, 11615918: 11615918
33 NKX2-5 NM_004387.3(NKX2-5): c.73C> T (p.Arg25Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs28936670 GRCh37 Chromosome 5, 172662014: 172662014
34 NKX2-5 NM_004387.3(NKX2-5): c.73C> T (p.Arg25Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs28936670 GRCh38 Chromosome 5, 173235011: 173235011
35 NKX2-5 NM_004387.3(NKX2-5): c.61G> C (p.Glu21Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104893904 GRCh37 Chromosome 5, 172662026: 172662026
36 NKX2-5 NM_004387.3(NKX2-5): c.61G> C (p.Glu21Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104893904 GRCh38 Chromosome 5, 173235023: 173235023
37 GATA4 NM_002052.4(GATA4): c.909+25G> A single nucleotide variant Conflicting interpretations of pathogenicity rs147860174 GRCh37 Chromosome 8, 11607770: 11607770
38 GATA4 NM_002052.4(GATA4): c.909+25G> A single nucleotide variant Conflicting interpretations of pathogenicity rs147860174 GRCh38 Chromosome 8, 11750261: 11750261
39 GATA4 NM_002052.4(GATA4): c.997+56C> A